Member Info for Bobat123

London South East
There's still time to register for tomorrow's webinar which is sponsored by PrimaryBid, featuring Zephyr Energy (ZPHR), SpectrumX, Scirocco Energy (SCIR) and Power Metal Resources (POW). Sign up here.

Share PricesCizzle Biotech Share PriceCizzle Biotech Share NewsTRADING UPDATES: Tritax EuroBox ups placing; Agronomics backs Vitro
Pin to quick picksCizzle Biotech Share News (CIZ)
CIZ Share Price
CIZ Share
Price
CIZ Share News
CIZ Share
News
1
CIZ Share Chat
CIZ Share
Chat
14
CIZ Share Trades
CIZ Share
Trades
50
CIZ Live RNS
CIZ
Live RNS
3
CIZ Information Buy CIZ SharesBuy CIZ SharesAdd CIZ to WatchlistAdd CIZ to WatchlistAdd CIZ to AlertAdd CIZ to AlertAdd CIZ to myTerminalAdd CIZ to myTerminal
Share Price Information for Cizzle Biotech (CIZ)
London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
4.94
Change:
0.04 (0.82%)
CIZ Live PriceLast checked at 22:06:05

CIZ News

CIZ Professional News
TRADING UPDATES: Tritax EuroBox ups placing; Agronomics backs Vitro
Mon, 20th Sep 2021 21:59
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Tritax EuroBox PLC - logistics real estate assets manager - Increases size of placing to GBP213 million after initially targetting GBP170 million. Says 191.2 million shares to be issued at 111.5 pence each. "In taking this decision the board has taken into account the strength of the manager's near-term investment pipeline," Tritax EuroBox says.

Agronomics Ltd - Isle of Man-based alternative proteins company - Leads funding round in investee VitroLabs Inc with a USD7.0 million investment. "The subscription is part of a funding round being undertaken by VitroLabs with the proceeds being used to build and scale the world's first pilot production facility of cultivated leather," Agronomics explains. Agronomics holds just shy of 15% VitroLabs stake and has right to board seat.

Cizzle Biotechnology Holdings PLC - London-based biotechnology firm - Lands agreement with biomedical charity St George Street Capital. Deal involves Cizzle being granted future royalty payments from commercialisation of St George Street Capital's AZD1656 Covid-19 treatment. Payments could reach GBP5 million. "While future royalties are contingent on the successful development of AZD1656, the recent clinical trial results are a positive step and Cizzle Biotechnology's royalty rights are not limited to the success of AZD1656 for treating Covid-19," Cizzle says.

20 September 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")



Agreement with St George Street Capital

Royalty agreement signed for potential COVID 19 treatment for diabetic patients and possible additional therapeutic indications

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce it has executed a royalty sharing agreement with St George Street Capital ("SGSC"), the UK-based biomedical charity. As announced on 22 June 2021, Cizzle Biotechnology signed a Memorandum of Understanding ("MoU") with SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to £5 million, plus potentially further payments from the use of a companion diagnostic. The full commercial contract in relation to this has now been entered into, following the announcement on 9 September 2021 of the encouraging clinical trial results from SGSC's ARCADIA trial. The trial was initiated from an existing collaboration between SGSC and AstraZeneca and funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme.

While future royalties are contingent on the successful development of AZD1656, the recent clinical trial results are a positive step and Cizzle Biotechnology's royalty rights are not limited to the success of AZD1656 for treating COVID 19. Cizzle Biotechnology's royalty rights also cover the use of AZD1656 for other diseases and AZD1656 has been shown to affect the immune system at sites of damaging inflammation which can be typical in autoimmune disease. Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656, Cizzle Biotechnology is to pay £135,000 to SGSC

Rns Out

Code 100 printed if you believe in codes. Mms looking for shares.

d2p - US FDA further approval for antibacterial plastic technology with greater loading and wider use in bread films

· d2p - Canadian Health approval for antibacterial bread films

· 4 significant collaboration agreements with Meditech

o China distribution agreement for d2w and d2p

o Manufacturing and royalty agreement for Nitrile gloves

o Marketing agreement for Symphony to sell d2p Nitrile gloves in specified markets

o Corporate agreement to acquire not less than 2.5% and not more than 20% of Symphony's total share capital



Commenting on the results Nicolas Clavel, Interim Chairman of Symphony, said:



During the period, the Group has substantially developed its highly relevant product range together with continuing major improvements in its key operations. This has resulted, amongst other achievements, in US FDA and Canadian approvals for Symphony's d2p bread packaging where the size of the market is vast, and where Symphony already has a presence with its d2w biodegradable technology. Other product areas are moving ahead strongly including d2p antimicrobial in pipes and tanks, together with insect and animal repellent technologies, amongst others. Symphony expects its d2p bread packaging and some of its other d2p projects to commercialise in the very near term.

Rns Out

Games being played by mms. Couple of less than 500 sells and they have taken the price down to 5.

One peep bought 43807 and sold out on over £200 plus loss.

Many peeps buying back after selling out on the cheap.

Peeps taking positions. Very undervalued.
Ticking up slowly. More contract news due soon. Many buys showing as sells.

Some peep accumulating daily while peeps are selling.

Mms took this down on bad news many months ago. This should be over 7p plus on news today. Vls mentioned in the States. Shows the worth of the company

Good news and the share tanks. Let the steady flow in rise continue then bring on the good news. Gla

Excellent Rns. Hopefully good day beckons

Velocys plc (VLS.L) welcomed the US Government announcement last week of a set of comprehensive new policy actions in support for Sustainable Aviation Fuel (SAF) production in the US. Velocys is cited in a White House briefing paper setting out the Biden administration's plans to incentivise commercial scale supply of SAF in the US to meet decarbonisation objectives while stimulating economic growth.

The briefing factsheet can be viewed at:

https://www.whitehouse.gov/briefing-room/statements-releases/2021/09/09/fact-sheet-biden-administration-advances-the-future-of-sustainable-fuels-in-american-aviation/

The central new policy incentive is a Sustainable Aviation Fuel tax credit as part of the Build Back Better Agenda. This credit will help cut costs and rapidly scale domestic production of sustainable fuels for aviation. The proposed tax credit requires at least a 50% reduction in lifecycle greenhouse gas emissions and offers increased incentive for greater reductions.

In addition, the US government plans to make available new and ongoing funding opportunities to support sustainable aviation fuel projects and fuel producers totalling up to $4.3 billion.

T his follows on from Velocys' announcement that the UK Government supported the Altalto SAF project in the UK with a grant award of GBP2.4m to British Airways and Velocys, and the Japanese Government support for our clients in Japan who are expected to use Velocys' patented FT technology for a commercial scale biorefinery producing SAF from woodchips.

Henrik Wareborn, Velocys CEO, said:

"The momentum in the transition away from fossil fuels into sustainable synthetic fuels is growing globally. Velocys proprietary Fischer Tropsch microchannel technology provides the core enabling conversion process for commercial scale production of SAF from a range of abundantly available sustainable feedstocks with no other alternative use.

"The announcement by the Biden administration last week provides critical support for our leading reference project in Mississippi supporting attractive investment returns for energy transition investors driving decarbonisation of aviation."

Looks like we have a seller. Once they are gone this will move. Tr1 coming any day.

Bought more. Big buys coming in now

St George Street has agreed to grant the company potential future royalty payments of up to GBP5 million, plus payments for the companion diagnostic, for the commercialisation of AZD1656. Previously, Cizzle signed a memorandum of understanding with St George Street, including an agreement to co-develop a companion diagnostic platform. Expects to receive fees of GBP1 million for the development of this platform.

2.4 million buy printed at 6.2 from yesterday

Big buys yesterday at over 6p plus. Many peeps selling out on the cheap. Also should see a tr1 on seller. Very undervalued.